CureVac has achieved good data for the COVID-19 vaccine candidate CVnCoV in preclinical studies. In mice and hamsters, this triggered a balanced humoral and cellular immune response, the Tübingen-based biotech company announced on Friday. High antibody and T-cell reactions have been observed, according to CureVac. “In addition to the positive immune response, the vaccine candidate was able to induce favorable Th1 cytokine levels. Furthermore, in a challenge study, CVnCoV offered hamsters effective protection against the living SARS-CoV-2 virus, without the vaccine-induced aggravation of the disease being able to be demonstrated, ”the southern Germans said.
The data has Curevac published on bioRvix and also submitted for possible publication in a peer-reviewed journal. CureVac also plans to publish interim data from clinical phase I with the vaccine candidate CVnCoV shortly. This is currently being investigated in phase 1 and phase 2a clinical studies, which means that CureVac is not yet as advanced in the development of its potential COVID-19 vaccine as BioNTech or Moderna. However, it is foreseeable that vaccines from a whole range of manufacturers will be required to combat the pandemic, among other things in order to obtain the necessary capacities.
“The preclinical data released today show that our COVID-19 vaccine candidate has the potential to induce an effective and balanced immune response that mimics natural immune defenses and fully protects the lungs in a relevant challenge animal model,” says Mariola Fotin -Mleczek, CureVac’s Chief Technology Officer. “The study greatly contributes to our understanding of CVnCoV, which is currently being investigated in phase 1 and 2a clinical trials,” said the CureVac manager.
At a glance – chart and news: CureVac